AVT05 is a biosimilar candidate to Johnson & Johnson's (JNJ) Simponi and Simponi Aria, also known by their generic name, golimumab, which are approved to treat a variety of inflammatory conditions.

In 2020, Alvotech and Teva entered into a strategic partnership for the exclusive commercialization of five of Alvotechs biosimilar product candidates, including AVT05. Since the companies entered ...

a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the U.S. FDA has accepted for review Biologics License Applications for AVT05, Alvotech’s proposed biosimilar to ...